Progression‐free survival (PSF) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension grade ≥ 3 · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · platinum‐sensitive recurrent EOC
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Progression‐free survival · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Quality of Life ‐ not reported · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Death (all causes) · women with locally advanced cervical cancer
Hysterectomy (radical) with neoadjuvant chemotherapy showed no clear difference in overall survival Median compared with chemoradiotherapy alone (moderate certainty).
1 finding from 1 review
Disease-free survival · women with locally advanced cervical cancer
Hysterectomy (radical) with neoadjuvant chemotherapy may leads to higher DFS Median compared with chemoradiotherapy alone (low certainty).
1 finding from 1 review
Quality of life · women with locally advanced cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs and toxicity · women with locally advanced cervical cancer
It is very uncertain whether hysterectomy (radical) with neoadjuvant chemotherapy changes SAEs and toxicity compared with chemoradiotherapy alone (very low certainty).
1 finding from 1 review
Death (all causes) · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy probably leads to lower overall survival Median compared with radiotherapy alone (moderate certainty).
1 finding from 1 review
Disease or progression‐free survival Median · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in disease‐ or progression‐free survival Median compared with radiotherapy alone (moderate certainty).
1 finding from 1 review
Quality of life · women with locally advanced cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events and toxicity · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in severe adverse events and toxicity compared with radiotherapy alone (low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).
1 finding from 1 review